Home Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
|

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

Print
Share
Sign up for the
DRFZ NewsFlash